These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 36384186)

  • 1. Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.
    Tsai MS; Sun HY; Chen CP; Lee CH; Lee CY; Liu CE; Tang HJ; Hung TC; Li CW; Lee YT; Liou BH; Yang CJ; Hung CC;
    Int J Infect Dis; 2023 Jan; 126():39-47. PubMed ID: 36384186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
    Andreatta K; Willkom M; Martin R; Chang S; Wei L; Liu H; Liu YP; Graham H; Quirk E; Martin H; White KL
    J Antimicrob Chemother; 2019 Dec; 74(12):3555-3564. PubMed ID: 31430369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
    Acosta RK; Willkom M; Andreatta K; Liu H; Martin R; Parvangada A; Martin H; Collins S; White KL
    J Acquir Immune Defic Syndr; 2020 Nov; 85(3):363-371. PubMed ID: 32701823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrase strand transfer inhibitor resistance mediated by R263K plus E157Q in a patient with HIV infection treated with bictegravir/tenofovir alafenamide/emtricitabine: case report and review of the literature.
    Buzon-Martin L; Navarro-San Francisco C; Fernandez-Regueras M; Sanchez-Gomez L
    J Antimicrob Chemother; 2024 May; 79(5):1153-1156. PubMed ID: 38558010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice.
    Armenia D; Forbici F; Bertoli A; Berno G; Malagnino V; Gagliardini R; Borghi V; Gennari W; Cicalini S; Buonomini A; Teti E; Lanini S; Latini A; Sarmati L; Mussini C; Andreoni M; Antinori A; Perno CF; Ceccherini-Silberstein F; Santoro MM
    J Glob Antimicrob Resist; 2022 Sep; 30():326-334. PubMed ID: 35793776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid Initiation of Antiretroviral Therapy With Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Versus Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate in HIV-Positive Men Who Have Sex With Men in China: Week 48 Results of the Multicenter, Randomized Clinical Trial.
    Wang R; Sun L; Wang X; Zhai Y; Wang L; Ma P; Wu C; Zhou Y; Chen R; Wang R; Zhang F; Hua W; Li A; Xia W; Gao Y; Li R; Lv S; Shao Y; Cao Y; Zhang T; Wu H; Cai C; Dai L
    Clin Infect Dis; 2024 Jul; 79(1):169-176. PubMed ID: 38236137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis.
    Chivite I; Berrocal L; de Lazzari E; Navadeh S; Lluis-Ganella C; Inciarte A; de la Mora L; González-Cordón A; Martínez-Rebollar M; Laguno M; Torres B; Blanco JL; Martínez E; Mallolas J; Ambrosioni J
    J Antimicrob Chemother; 2024 Aug; 79(8):1775-1783. PubMed ID: 38758191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bictegravir/emtricitabine/tenofovir alafenamide in paediatrics: Real-life experience from a French cohort (2019-2023).
    Frange P; Veber F; Burgard M; Blanche S; Avettand-Fenoel V
    HIV Med; 2024 Feb; 25(2):299-305. PubMed ID: 37807595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide.
    Liou BH; Cheng CN; Lin YT; Lin YJ; Chuang YC; Lin KY; Liu WC; Lin SW; Kuo CH; Sun HY; Hung CC
    J Int AIDS Soc; 2021 Nov; 24(11):e25844. PubMed ID: 34822220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
    Hagins D; Kumar P; Saag M; Wurapa AK; Brar I; Berger D; Osiyemi O; Hileman CO; Ramgopal MN; McDonald C; Blair C; Andreatta K; Collins SE; Brainard DM; Martin H;
    J Acquir Immune Defic Syndr; 2021 Sep; 88(1):86-95. PubMed ID: 34397746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens.
    Chen GJ; Sun HY; Chen LY; Hsieh SM; Sheng WH; Liu WD; Chuang YC; Huang YS; Lin KY; Wu PY; Chang HY; Luo YZ; Su YC; Liu WC; Chang SF; Chang SY; Hung CC
    Int J Antimicrob Agents; 2022 Sep; 60(3):106631. PubMed ID: 35787920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Multicentre Cohort: Real-Life Experience From Spain.
    Torralba M; Rodríguez G; González Gasca FJ; Cuadra F; Barberá J; Geijo P; Silva A; García MI; Ostaiza MA; García Pérez AM; Arroyo E; Larrubia JR; Gutiérrez A; Porras ML; Calvo Sánchez H; Peña-Asensio J; Arias JG; Mendoza I
    Ann Pharmacother; 2024 Feb; 58(2):140-147. PubMed ID: 37131300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of second-generation integrase strand-transfer inhibitor-based regimens for antiretroviral-experienced people with HIV who had viral rebound.
    Chen GJ; Sun HY; Chang SY; Hsieh SM; Sheng WH; Chuang YC; Huang YS; Lin KY; Liu WC; Su YC; Hung CC
    J Microbiol Immunol Infect; 2023 Oct; 56(5):988-995. PubMed ID: 37574435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.
    Nasreddine R; Florence E; Yombi JC; Henrard S; Darcis G; Van Praet J; Vandekerckhove L; Allard SD; Demeester R; Messiaen P; Ausselet N; Delforge M; De Wit S;
    HIV Med; 2023 Aug; 24(8):914-924. PubMed ID: 37038245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment-emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series.
    DeKoven S; Naccarato M; Brumme CJ; Tan DHS
    HIV Med; 2023 Nov; 24(11):1137-1143. PubMed ID: 37317505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
    Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
    Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre.
    Ambrosioni J; Rojas Liévano J; Berrocal L; Inciarte A; de la Mora L; González-Cordón A; Martínez-Rebollar M; Laguno M; Torres B; Ugarte A; Chivite I; Leal L; de Lazzari E; Miró JM; Blanco JL; Martinez E; Mallolas J
    J Antimicrob Chemother; 2022 Mar; 77(4):1133-1139. PubMed ID: 35040990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
    Eron JJ; Orkin C; Cunningham D; Pulido F; Post FA; De Wit S; Lathouwers E; Hufkens V; Jezorwski J; Petrovic R; Brown K; Van Landuyt E; Opsomer M;
    Antiviral Res; 2019 Oct; 170():104543. PubMed ID: 31279073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort study.
    Gan L; Xie X; Fu Y; Yang X; Ma S; Kong L; Song C; Song Y; Ren T; Long H
    BMC Infect Dis; 2024 Jun; 24(1):565. PubMed ID: 38844855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial.
    Iwuji CC; Churchill D; Bremner S; Perry N; To Y; Lambert D; Bruce C; Waters L; Orkin C; Geretti AM
    BMC Infect Dis; 2020 Jul; 20(1):524. PubMed ID: 32689975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.